北京中伦文德（杭州）律师事务所 关于 诚达药业股份有限公司 2026 年第一次临时股东会的 法律意见书 北京中伦文德（杭州）律师事务所 地址：杭州市萧山区钱江世纪城广孚中心 1301 电话：0571-83685215 传真：0571-83685215 邮编：311200 北京中伦文德（杭州）律师事务所 法律意见书 北京中伦文德（杭州）律师事务所 关于诚达药业股份有限公司 2026 年第一次临时股东会的 法律意见书 致：诚达药业股份有限公司 北京中伦文德（杭州）律师事务所（以下称"本所"）接受诚达药业股份有 限公司（以下称"公司"）的委托，指派律师出席公司 2026 年第一次临时股东 会（以下称"本次股东会"），本所律师根据《中华人民共和国公司法》（以下 称"《公司法》"）、《中华人民共和国证券法》（以下称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所上 市公司股东会网络投票实施细则》等法律、法规和规范性法律文件以及《诚达药 业股份有限公司章程》（以下称"《公司章程》"）的规定，就公司本次股东会 的召集召开程序、出席会议人员的资格、召集人的资格、表决程序和表决结果等 ...

证券代码：301201 证券简称：诚达药业 公告编号：2026-001 诚达药业股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2、召开地点：浙江省嘉兴市嘉善县惠民街道黄河路 36 号诚达药业股份有限 公司会议室。 特别提示： 1、本次股东会不存在否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2026 年 1 月 6 日（星期二）下午 14：00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2026 年 1 月 6 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网投票的具体时间为：2026 年 1 月 6 日 9:15—15:00。 3、召开方式：本次股东会采用现场表决与网络投票相结合的方式召开。 4、召集人：董事会 5、主持人：董事长葛建利女士 6、本次会议的召集、召开符合《中华人民共和国公司法》、《上市公司股 东会规则》、《深圳证 ...

Group 1 - The core viewpoint is that small nucleic acid drugs are expected to become the main focus of the global pharmaceutical industry by 2026, driven by advancements in precision medicine and the transition from traditional chemical and biological drugs to targeted therapies [2][3] - Small nucleic acid drugs, as a third-generation therapy capable of intervening in disease processes at the genetic level, are seen as a disruptive innovation, with significant contributions expected from biotech leaders like Arrowhead [2] - The development of small nucleic acid drugs is anticipated to stimulate global pipeline transactions, with companies like Rego Bio focusing on RNA interference (RNAi) for chronic disease treatment [2][3] Group 2 - Rego Bio, established in 2007, specializes in the development of RNAi technology and small nucleic acid drug commercialization, creating a comprehensive R&D platform for small nucleic acid drugs targeting various diseases, particularly chronic conditions [3] - Investment recommendations include focusing on small nucleic acid CDMO companies and key raw material producers that meet FDA audit standards, with specific companies highlighted such as Chengda Pharmaceutical and WuXi AppTec [3]

Core Viewpoint - The innovative drug sector in China is experiencing significant growth, with a record number of approved innovative drugs and substantial increases in licensing transactions, indicating a strong market potential and investment opportunities in the pharmaceutical industry [1] Industry Summary - As of 2025, China has approved 76 innovative drugs, surpassing the 48 approved in 2024, marking a historical high [1] - The total value of licensing transactions for innovative drugs in China is expected to exceed $130 billion, with over 150 transactions, also a historical high [1] - The pharmaceutical research outsourcing sector is benefiting from a recovery in industry demand, with companies like WuXi AppTec and Hao Yuan Medical showing excellent growth [1] Company Summary - Companies in the innovative drug sector, such as Lepu Medical, Frontier Biotechnologies, and BeiGene, have seen significant stock price increases, with Lepu Medical hitting a 20% limit up and others like Frontier Biotechnologies rising over 13% [1] - The innovative drug industry's core driving factor is the breakthrough in global competitiveness of Chinese pharmaceutical companies, which are gaining recognition for their research capabilities [1] - The demand for CXO and research services within the innovative drug supply chain is expected to continue benefiting from favorable market conditions, leading to sustained performance exceeding expectations [1]

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, closing at 40.70 yuan with a drop of 3.85%, indicating it is in a state of breaking below its initial public offering price [1] Group 1: IPO and Financials - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest price recorded on the first day of trading was 188.00 yuan, marking the peak since its listing [1] - The total funds raised from the IPO amounted to 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original target by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including pharmaceutical intermediates, raw materials, and R&D center expansion [1] Group 2: Shareholder Returns - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares held [2] - The record date for this equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [2] Group 3: Management - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin holding Canadian permanent residency [2]

光大证券股份有限公司 培训地点：诚达药业会议室 培训对象：公司实际控制人以及部分董事、监事、高级管理人员 二、培训内容 本次现场培训前，光大证券制作了培训讲义，并提前向公司发出了关于本次 培训的通知。 本次培训主要对深交所于 2025 年修订发布的《上市公司自律监管指引第 2 号-创业板上市公司规范运作》进行了重点讲解。 关于诚达药业股份有限公司 2025 年度现场培训情况报告 光大证券股份有限公司（以下简称"光大证券"、"保荐机构"）作为诚达 药业股份有限公司（以下简称"诚达药业"、"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《深圳证券交易所上市公司自律监管指引第 13 号 ——保荐业务》等有关规定，于 2025 年 12 月 16 日对公司实际控制人以及部分 董事、监事、高级管理人员进行了现场培训，现将培训情况报告如下： 一、培训基本情况 培训时间：2025 年 12 月 16 日 （以下无正文） （此页无正文，为《光大证券股份有限公司关于诚达药业股份有限公司2025 年度现场培训情况报告》之签字盖章页） 保荐代表人： 杨科 韩剑龙 光大证券股份有限公司 2025 年 12 月 30 日 三 ...

光大证券股份有限公司关于 诚达药业股份有限公司 2025年度持续督导现场检查报告 | 保荐人名称：光大证券股份有限公司 被保荐公司简称：诚达药业 | | --- | | 保荐代表人姓名：杨科 联系电话：021-22169999 | | 保荐代表人姓名：韩剑龙 联系电话：021-22169999 | | 现场检查人员姓名：杨科、耿忠良 | | 现场检查对应期间：2025 年度 | | 现场检查时间：2025 年 12 月 16 日 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段： | | 查阅公司相关规章制度、三会文件、信息披露文件；访谈公司实际控制人、董事 | | 会秘书、财务总监等人员。 | | 1.公司章程和公司治理制度是否完备、合规 √ | | √ 2.公司章程和股东会、董事会规则是否得到有效执行 | | 3.股东会、董事会会议记录是否完整，时间、地点、出席 √ | | 人员及会议内容等要件是否齐备，会议资料是否保存完整 | | 4.股东会、董事会会议决议是否由出席会议的相关人员签 √ | | 名确认 | | 5.公司董事、高级管理人员是否按照有关法 ...

Group 1 - The core point of the article is that Chengda Pharmaceutical has received a notice regarding the progress of a share reduction plan by Qianhai Shengtai, which has reduced its holdings by approximately 2.91 million shares, accounting for 1.92% of the total share capital after excluding repurchased shares [1] - As of the end of 2024, Chengda Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 55.67%, food manufacturing accounts for 43.0%, other businesses account for 0.69%, and trading revenue accounts for 0.65% [1] - The current market capitalization of Chengda Pharmaceutical is 6.6 billion yuan [1]

持股 5%以上股东深圳前海晟泰投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：301201 证券简称：诚达药业 公告编号：2025-057 诚达药业股份有限公司 关于持股 5%以上股东减持计划时间届满的公告 公司于近日收到前海晟泰出具的《关于股份减持计划实施进展告知函》， 获悉截止 2025 年 12 月 28 日，前海晟泰减持计划实施期限已届满，期间累计减 持公司股份 2,906,400 股，占公司剔除回购专户股份数后总股本比例 1.92%。根 据《中华人民共和国证券法》《深圳证券交易所上市公司自律监管指引第 18 号 ——股东及董事、高级管理人员减持股份》等相关规定，现将相关情况公告如下： 一、股东减持情况 | 股东名称 | 减持方式 | 减持期间 | | 减持均价 （元/股） | 减持股数（股） | 减持股数占 剔除回购专 户股份数后 | 减持股数 占总股本 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 总股本比例 | 比例（%） | | | | | | ...

Group 1 - The core viewpoint of the news is that Chengda Pharmaceutical's stock performance and financial metrics indicate a mixed outlook, with significant financing activity and a notable decline in net profit despite revenue growth [1][2]. Group 2 - On December 24, Chengda Pharmaceutical's stock fell by 0.86%, with a trading volume of 151 million yuan. The financing buy-in amount for the day was 18.04 million yuan, while the financing repayment was 12.14 million yuan, resulting in a net financing buy of 5.90 million yuan. The total financing and securities balance reached 263 million yuan [1]. - The financing balance of Chengda Pharmaceutical is 263 million yuan, accounting for 4.11% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - As of December 24, there were no shares repaid or sold in the securities lending market, with a securities lending balance of 0 yuan, which is also at a high level compared to the past year [1]. Group 3 - As of September 30, the number of shareholders for Chengda Pharmaceutical was 12,700, a decrease of 8.58% from the previous period. The average circulating shares per person increased by 36.16% to 8,577 shares [2]. - For the period from January to September 2025, Chengda Pharmaceutical achieved operating revenue of 285 million yuan, representing a year-on-year growth of 16.95%. However, the net profit attributable to the parent company was 16.77 million yuan, a decrease of 58.47% year-on-year [2]. Group 4 - Chengda Pharmaceutical has distributed a total of 133 million yuan in dividends since its A-share listing, with cumulative distributions of 89.62 million yuan over the past three years [3].